Replies to post #111296 on Biotech Values

[DewDiligence]

(MNTA)—Eliquis update from PFE’s 2Q11 CC: CEO Ian Read said PFE will submit the Eliquis NDA in AF/stroke prevention during 2H11, but Read said nothing whatsoever about submitting an NDA for Eliquis in VTE prevention. Thus, my contention in #msg-58061618 that an Eliquis NDA in VTE prevention is problematic appears to be corroborated.

If PFE (or BMY) had said that the Eliquis dossier in VTE prevention was worthy of an NDA, I might have had to adjust the numbers in Paragraph B of #msg-64862315, where I forecasted a 50-60% loss of US Lovenox sales for VTE prevention following orthopedic surgery (contributing to a 28% drop in overall US Lovenox sales). However, as things stand, the numbers in Paragraph B of #msg-64862315 need not be changed because I assumed the Lovenox share loss in this indication was entirely due to gains by Xarelto, not Eliquis.